Current therapies for chronic lymphocytic leukemia: risk and prophylaxis strategies for secondary/opportunistic infections
Lucia Diella(Humanitas University), Attilio Guarini(Istituto Tumori Bari), Davide Fiore Bavaro(Humanitas University), Carla Minoia(Istituto Tumori Bari), Giacomo Loseto(Istituto Tumori Bari), Maria Stella De Candia(Istituto Tumori Bari), Crescenza Pasciolla(Istituto Tumori Bari), Annalisa Saracino(University of Bari Aldo Moro), Daniela Di Gennaro(University of Bari Aldo Moro), Francesco Di Gennaro(University of Bari Aldo Moro), Alessandra Belati(Humanitas University)
Cited by 4
Related Papers
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study
|Clinical Infectious Diseases|2021|264
Incidence of long COVID-19 in people with previous SARS-Cov2 infection: a systematic review and meta-analysis of 120,970 patients
|Internal and Emergency Medicine|2022|113